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Abstract
Background:  CD10 antigen is a 100-kDa-cell surface zinc metalloendopeptidase and it is
expressed in a variety of normal and neoplastic lymphoid and nonlymphoid tissues. The aim of this
study was to evaluate CD10 expression in urothelial carcinoma of the urinary bladder and to
determine the correlation between immunohistochemical (IHC) CD10 expression and
histopathologic parameters including grade and stage.
Methods: 371 cases of urothelial bladder carcinomas, all from transurethral resections, were
included in this study. Hematoxylin-eosin (HE) stained sections from each case were reevaluated
histopathologically according to WHO 2004 grading system. The TNM system was used for
pathologic staging. Selected slides were also studied by IHC and a semiquantitative scoring for
CD10 expression based on the percentage of positive cells was performed.
Results: 157 cases (42.3%) showed immunostaining while 214 cases (57.7%) were negative for
CD10. 1+ staining was seen in 65 CD10 positive cases (41.4%), and 2+ in 92 cases (58.6%). Overall
CD10 expression as well as 2+ immunostaining was significantly correlated with high histologic
grade. Overall CD10 expression was also significantly higher in invasive pT1 and pT2-3 tumors
compared to noninvasive pTa tumors. pT1 and pT2-3 tumors were also significantly correlated
with 2+ immunostaining.
Conclusion: To date, only a few comparative IHC studies have assessed CD10 expression in
urothelial carcinoma of the urinary bladder and this study represents the largest series. Our
findings indicate that CD10 expression is strongly correlated with high tumor grade and stage in
urothelial carcinoma of the bladder, and that CD10 may be associated with tumor progression in
bladder cancer pathogenesis.
Background
Cancer of the bladder represents the ninth most common
cause of cancer worldwide and the 13th most numerous
cause of death from cancer with an estimated 357,000
newly diagnosed cases and 145,000 cancer-related deaths
in 2002 [1]. Most patients (70-80%) with newly diag-
nosed urothelial carcinoma of the bladder present with
well-differentiated superficial papillary tumors. Pro-
longed survival in most patients with superficial cancers is
achieved by transurethral resection (TUR) with or without
Published: 16 November 2009
Diagnostic Pathology 2009, 4:38 doi:10.1186/1746-1596-4-38
Received: 21 August 2009
Accepted: 16 November 2009
This article is available from: http://www.diagnosticpathology.org/content/4/1/38
© 2009 Bahadir et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Diagnostic Pathology 2009, 4:38 http://www.diagnosticpathology.org/content/4/1/38
Page 2 of 7
(page number not for citation purposes)
intravesical chemotherapy [2-6]. Nonetheless, these
patients still have a high risk of recurrence following ini-
tial resection [7]. The major prognostic factors in carci-
noma of the bladder are the depth of invasion into the
bladder wall and the degree of differentiation of the
tumor. However, there is no reliable parameter predicting
the risk of recurrence or progression. Molecular markers
are, therefore, required to estimate the individual progno-
sis of patients as well as for effective diagnosis and treat-
ment.
CD10 is a single-chain, 90-110-kDa cell surface zinc-
dependent metalloprotease that inactivates various bioac-
tive neuropeptides. Terms synonymous with CD10
include common acute lymphocytic leukemia antigen
(CALLA), enkephalinase, membrane metalloendopepti-
dase (MME), membrane-associated neutral endopepti-
dase (NEP 24.11), and neprilysin [8-10]. Initially it was
discovered on the surface of acute lymphoblastic leuke-
mia cells, and considered to be a tumor-specific antigen
[11]. It was then found that a variety of normal cells
including cells of nonhematopoietic origin such as
glomerular and proximal tubular epithelium of the kid-
ney, liver, breast myoepithelium, and lung, as well as
fibroblasts and cells of the central nervous system are able
to express CD10 [8,9,12-18]. CD10 is expressed by a
number of hematopoietic cells such as immature T and B
cells, B cells of the germinal centers of lymphoid follicles,
and granulocytes as well as lymphoid malignancies
including the majority of acute lymphoblastic leukemia,
and also follicular center lymphoma, lymphoblastic,
Burkitt's, and nodular poorly differentiated lymphocytic
lymphomas, and chronic myelogenous leukemias in lym-
phoid blast crisis [19-22]. CD10 expression has also been
reported in several nonhematopoietic neoplasms includ-
ing renal cell carcinoma, endometrial stromal tumor,
solid and pseudopapillary tumor of the pancreas,
melanoma, carcinoma of the prostate, breast, stomach,
and colon [16,23-32].
CD10 has a neutral endopeptidase activitiy and is known
to regulate biological activities of peptide substrates
including atrial natriuretic factor, endothelin, oxytocin,
bradykinin, substance P angiotensins, enkephalins and
bombessin-like peptides by reducing the local concentra-
tions available for receptor binding and signal transduc-
tion [9,10,33,34]. Recent evidence also demonstrated a
correlation between apoptosis and CD10 expression [35-
38]. It may also play an important role in maintenance of
homeostasis, neoplastic transformation, and tumor pro-
gression [39-41]. CD10 expression in intratumoral stro-
mal cells may also contribute to tumor progression [42].
To date, only a few studies have investigated CD10 expres-
sion in urothelial carcinoma of the urinary bladder [43-
46]. In the current study, we evaluated 371 urothelial car-
cinomas of the urinary bladder and sought to determine
the correlation, if any, between IHC CD10 expression and
histopathologic parameters including grade and stage and
to find out whether CD10 expression could have a prog-
nostic value in the assessment of urothelial cancer.
Methods
371 consecutive cases of papillary urothelial neoplasms of
the bladder were included in this study. All tumor speci-
mens were from transurethral resections. HE stained sec-
tions from formalin-fixed, paraffin-embedded material
were reevaluated histopathologically. Tumors were sub-
classified as papillary neoplasm of low malignant poten-
tial, as low-grade papillary carcinoma, or as high-grade
papillary carcinoma according to the WHO 2004 grading
system [47]. The TNM system was used for pathologic
staging: Ta, noninvasive papillary urothelial carcinoma;
T1, tumor invades subepithelial connective tissue; T2,
tumor invades muscularis propria, and T3, tumor invades
perivesical tissue [48].
IHC was performed using a streptavidin-biotin-peroxi-
dase technique (UltraVision, Lab Vision, Fremont, CA,
USA) with a monoclonal antibody to CD10 (NeoMarkers,
Lab Vision, Fremont, CA, USA). 5-μm sections from par-
affin-embedded samples were cut on poly-L-lysine coated
slides, deparaffinized in xylene, and then dehydrated. For
antigen retrieval, the slides were treated by microwave
heating in citrate buffer (pH 6.0) for 10 minutes. 3%
hydrogen peroxide was used for blocking endogenous
peroxidase activity. The sections were incubated with pri-
mary antibody including CD10 at 1:50 dilution for one
hour at room temperature. After washing in phosphate
buffered saline, the samples were incubated with a biotin
conjugated secondary antibody and then incubated using
streptavidin-biotin system for 30 minutes at room tem-
perature. The reactions became visible after immersion of
the specimens in diaminobenzidine tetrahydrochloride.
The sections were counterstained with hematoxylin, then
rinsed and mounted. Sections from nonneoplastic blad-
der mucosa were included as controls. Additional sections
of renal tissue were also used as positive control. Staining
of the cell membrane and/or cytoplasm was considered
positive expression. A semiquantitative scoring based on
the percentage of positive cells was performed according
to the following staining criteria: -, negative (<5%); 1+ (5-
50%); and 2+ (>50%).
Statistical analysis was performed using Statistical Package
for Social Sciences v 10.0 (SPSS Inc., Chicago, IL, USA)
software for Windows. Statistical significance of the
results was evaluated by χ2 test. P values <0.05 were con-
sidered statistically significant.Diagnostic Pathology 2009, 4:38 http://www.diagnosticpathology.org/content/4/1/38
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Results
The age of the patients ranged from 24 to 88 (mean ± SD
61.36 ± 9.74). Among 371 cases, 330 were (88.9%) male
and 41 (11.1%) female with an average male to female
ratio of 8:1. All 371 bladder neoplasms were low- or high-
grade papillary urothelial carcinomas; no case of papillary
neoplasm of low malignant potential was detected. 222
cases displayed low-grade morphology while 149 were
high grade carcinomas. Considering the pathologic stages,
279 patients had pTa, 53 pT1, and 39 pT2-3. Only 2 cases
were stage pT3 in the pT2-3 group.
Predominant IHC CD10 staining was cytoplasmic, but
membranous staining was also observed. Table 1 shows
the overall CD10 expression according to the histologic
grade and pathologic stage. 157 of the 371 cases (42.3%)
showed CD10 immunostaining while 214 cases (57.7%)
were negative for CD10. C010 immunoreaction was
higher with higher histologic grade (p < 0.0001). CD10
expression was also significantly higher in stages pT1 and
pT2-3 than in stage pTa (p < 0.0001).
Table 2 demonstrates the individual CD10 staining scores
in 157 cases with positive expression according to the his-
tologic grade and pathologic stage. 1+ expression was seen
in 65 cases (41.4%) while 92 cases (58.6%) demonstrated
2+ staining. 2+ immunostaining strongly correlated with
high grade (p < 0.0001). pT1 and pT2-3 tumors also sig-
nificantly correlated with 2+ immunostaining (p <
0.0001) (Figure 1, Figure 2, Figure 3, Figure 4).
Discussion
High recurrence rate in urothelial carcinoma of the blad-
der is a vital problem despite the improving treatment
options. The risk of bladder cancer recurrence following
initial resection in patients with Ta or T1 tumors may be
as high as 80% [7]. A number of molecular markers
reported to be of prognostic value have been well-studied.
Including these are blood group antigens, tumor suppres-
sor gene p53, cell cycle regulator proteins p27 and cyclin
E, E-cadherin, CD44 and many others [49-58]. However,
there are still conflicting results although some of them
may be attributed to different staining protocols or
patient selections [59].
In the current study, we demonstrated CD10 IHC expres-
sion in 42.3% of the urothelial carcinomas of the bladder.
CD10 staining of the malignant cells revealed a strong cor-
relation not only with histologic grade but also with path-
ologic stage. Moreover, percentage of CD10 staining
appeared to increase with higher grade; 91 of the 121 high
grade carcinomas showed 2+ reaction. Vast majority of the
low-grade carcinomas had 1+ staining pattern. The same
was true for invasive tumors: 2+ reaction was seen in 32 of
45 pT1 carcinomas and in 30 of 37 pT2-3 carcinomas.
Although pTa tumors mainly expressed 1+ reaction, a
somewhat balanced distribution was observed in staining
scores in this group.
The first study assessing CD10 activity in bladder was per-
formed by Koiso et al [43]. They found that both enzyme
activity and IHC expression were higher in superficial can-
cers than invasive cancers and normal urothelium. They
concluded that CD10 was expressed at a certain stage of
differentiation in the course of neoplastic process. The
absence of IHC CD10 expression in nonneoplastic
urothelium was shown after the development of CD10
monoclonal antibody appropriate for paraffin-embedded
tissues [33]. Chu and Arber reported positive cytoplasmic
staining in 13 of 24 (54%) urothelial carcinomas, while
there was no reaction in nonneoplastic tissues [23]. How-
ever, the correlation of CD10 expression with pathologic
stage or histologic grade was not investigated in that
study. These results suggest that neoplastic tissues rather
than nonneoplastic epithelium have a propensity for
CD10 expression. Conversely, Murali et al demonstrated
CD10 staining in 5 of the 10 cases of nonneoplastic
urothelium [44]. Despite the small number of cases, they
found CD10 expression in 80% of invasive carcinomas
and also proved that the staining intensity for the high-
Table 1: Overall CD10 expression according to the histologic grade and pathologic stage
CD10 Total
Negative No. (%) Positive No. (%)
Grade
Low-grade 186 (83.8%) 36 (16.2%) 222 (59.8%)
High-grade 28 (18.8%) 121* (81.2%) 149 (40.2%)
Stage
pTa 204 (73.1%) 75 (26.9%) 279 (75.2%)
pT1 8 (15.1%) 45* (84.9%) 53 (14.3%)
pT2-3 2 (5.1%) 37* (94.9%) 39 (10.5%)
*High-grade vs. low-grade; pT1 and pT2-3 vs. pTa: p < 0.0001Diagnostic Pathology 2009, 4:38 http://www.diagnosticpathology.org/content/4/1/38
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grade group (including invasive carcinoma, high-grade
papillary urothelial carcinoma, and carcinoma in situ)
was statistically higher than that of the low-grade group
(including low-grade papillary urothelial carcinoma, pap-
illary urothelial neoplasm of low malignant potential and
normal urothelium). In another study by Bircan et al, 34
of 79 (43%) urothelial carcinomas and only one case of
nonneoplastic epithelium showed CD10 staining [45].
They found an inverse correlation between CD10 expres-
sion and tumor stage, but no association with histologic
grade or staining score was detected. The authors pro-
posed that the higher level of CD10 expression in nonin-
vasive carcinomas appears to inhibit cell invasion. In a
more recent series of 49 cases by Abdou et al, CD10
expression significantly correlated with some parameters
including advanced stage, tumor size, and shorter mean
survival but not with grade [46]. The authors suggested
that CD10 appears to be associated with tumor progres-
sion and that it could play a pivotal role in bladder cancer
pathogenesis, a proposal also supported by our findings.
Apparently, our study-in which CD10 staining increased
with grade and stage-bears some similarities with and
shows some differences from these previous reports.
There may be several possibilities about the role of CD10
in urothelial tumorigenesis. First, CD10 is a cell surface
Noninvasive (pTa) papillary urothelial carcinoma demonstrat- ing strong (thick arrows) and weak (thin arrows) CD10 immu- nostaining Figure 1
Noninvasive (pTa) papillary urothelial carcinoma 
demonstrating strong (thick arrows) and weak (thin 
arrows) CD10 immunostaining.
Another example of noninvasive (pTa) papillary urothelial  carcinoma showing strong CD10 expression Figure 2
Another example of noninvasive (pTa) papillary 
urothelial carcinoma showing strong CD10 expres-
sion.
CD10 expression in invasive (pT1) papillary urothelial carci- noma Figure 3
CD10 expression in invasive (pT1) papillary urothe-
lial carcinoma. Intense staining corresponds to cells with 
high grade histology (arrows).
Diffuse CD10 immunostaining in invasive (pT2) urothelial  carcinoma Figure 4
Diffuse CD10 immunostaining in invasive (pT2) 
urothelial carcinoma. Membranous and cytoplasmic stain-
ing is best appreciated in the inset.Diagnostic Pathology 2009, 4:38 http://www.diagnosticpathology.org/content/4/1/38
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metalloprotease and one can easily postulate that CD10
expressing tumors have the capacity to create a microenvi-
ronment that facilitates cancer cell invasion and metasta-
sis [42,60,61]. This appears the most likely explanation
for the significant correlation of CD10 with grade and
stage in our study. If this is the case, it may also be specu-
lated that since invasive bladder carcinomas most likely
originate from high-grade noninvasive lesions rather from
low-grade tumors [62-64], tumors with high grade and
stage seem more likely to express CD10. Another possible
mechanism is that the increased IHC CD10 expression
with increasing grade and stage may indicate accumula-
tion of mutated, nonfunctional CD10 rather than its nor-
mal counterpart [44].
On the other hand, it was recently found that CD10
expression was associated with higher apoptotic index in
diffuse large B cell lymphoma [65]. Several hypothesis
have been proposed about the potential role of CD10 dur-
ing apoptosis. CD10 could prevent the cells' possible res-
cue from apoptosis by degrading cytokines capable of
delivering anti-apoptotic signals, or by degrading peptide
signals [37]. Moreover, CD10 expression may take part in
preventing unwanted inflammatory reaction initiated by
activated cells undergoing apoptosis, and it may protect
these cells from potential attacks by the immune system
[37,66]. Consequently, the contribution of CD10 to the
neoplastic process appears multifaceted and may be
related with other additional factors.
Indeed, the results of several studies in human tumors
other than urothelial carcinoma have also revealed that
changes in CD10 activity produce different influences in
different tumor types. Neoplasms arising from tissues that
normally express CD10 such as endometrial stromal
tumors, renal cell carcinoma, trophoblastic tumors, and
solid and pseudopapillary tumor of the pancreas may also
express this antigen [23-27,67,68]. CD10 also acts as a key
marker in differentiating endometrial stromal sarcoma
from smooth muscle tumors [24]. By contrast, low or
absent CD10 expression have been reported in several
tumors including small cell and non-small cell carcinoma
of the lung, and carcinomas of breast, stomach, and colon
[18,42,69-71]. It has been shown that CD10 promotes
apoptosis and inhibits cell migration in prostate carci-
noma [38,72]. Accordingly, CD10 expression diminishes
with tumor progression, particularly in metastatic, andro-
gen-independent prostate cancers [41]. On the other
hand, studies in melanomas have shown that CD10
expression correlates with tumor progression and metas-
tasis [29-31]. Bilalovic et al found that CD10 expression
was significantly higher in primary melanomas with
higher Clark level and larger Breslow thickness [31]. These
findings are somewhat parallel to our results, since Clark
level and larger Breslow thickness are two important prog-
nostic determinates associated with metastasis in
melanoma and the same is true for tumor grade and stage
in bladder carcinoma. Stromal CD10 expression has also
been observed in colorectal adenomas and carcinomas,
and in invasive ductal carcinomas of the breast but not in
normal tissues, a finding supporting the hypothesis that
CD10 may facilitate invasion and metastasis [70,71,42].
Therefore, it appears that CD10 may contribute to the
neoplastic processes in different tissue types, probably by
different or incompletely understood mechanisms.
Conclusion
This study represents the largest series of urothelial carci-
noma of the bladder examined for CD10 immunoexpres-
sion in relation to histologic grade and pathologic stage.
We found that CD10 expression is strongly correlated
with tumor grade and stage in urothelial carcinoma of the
bladder, and that CD10 may be associated with tumor
progression in bladder cancer pathogenesis. Although the
exact biologic function of CD10 and mechanisms of
action by which it regulates neoplastic process as well as
its significance in different types of tissues are not yet
clear, it may provide an additional parameter for evaluat-
ing bladder tumors. Further studies with large number of
cases are needed to confirm our results and to elucidate
the role and significance of CD10 in urothelial carcinoma.
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